176 related articles for article (PubMed ID: 1403041)
1. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
Lum BL; Kaubisch S; Yahanda AM; Adler KM; Jew L; Ehsan MN; Brophy NA; Halsey J; Gosland MP; Sikic BI
J Clin Oncol; 1992 Oct; 10(10):1635-42. PubMed ID: 1403041
[TBL] [Abstract][Full Text] [Related]
2. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic considerations.
Lum BL; Fisher GA; Brophy NA; Yahanda AM; Adler KM; Kaubisch S; Halsey J; Sikic BI
Cancer; 1993 Dec; 72(11 Suppl):3502-14. PubMed ID: 7902206
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.
Yahanda AM; Alder KM; Fisher GA; Brophy NA; Halsey J; Hardy RI; Gosland MP; Lum BL; Sikic BI
J Clin Oncol; 1992 Oct; 10(10):1624-34. PubMed ID: 1403040
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance.
Bartlett NL; Lum BL; Fisher GA; Brophy NA; Ehsan MN; Halsey J; Sikic BI
J Clin Oncol; 1994 Apr; 12(4):835-42. PubMed ID: 8151326
[TBL] [Abstract][Full Text] [Related]
6. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
Raschko JW; Synold TW; Chow W; Coluzzi P; Hamasaki V; Leong LA; Margolin KA; Morgan RJ; Shibata SI; Somlo G; Tetef ML; Yen Y; ter Veer A; Doroshow JH
Cancer Chemother Pharmacol; 2000; 46(5):403-10. PubMed ID: 11127945
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
Boote DJ; Dennis IF; Twentyman PR; Osborne RJ; Laburte C; Hensel S; Smyth JF; Brampton MH; Bleehen NM
J Clin Oncol; 1996 Feb; 14(2):610-8. PubMed ID: 8636778
[TBL] [Abstract][Full Text] [Related]
9. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
List AF; Spier C; Greer J; Wolff S; Hutter J; Dorr R; Salmon S; Futscher B; Baier M; Dalton W
J Clin Oncol; 1993 Sep; 11(9):1652-60. PubMed ID: 8102639
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporin A as a multidrug-resistant modulator in patients with renal cell carcinoma treated with teniposide.
Toffoli G; Sorio R; Gigante M; Corona G; Galligioni E; Boiocchi M
Br J Cancer; 1997; 75(5):715-21. PubMed ID: 9043030
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
12. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
Erlichman C; Moore M; Thiessen JJ; Kerr IG; Walker S; Goodman P; Bjarnason G; DeAngelis C; Bunting P
Cancer Res; 1993 Oct; 53(20):4837-42. PubMed ID: 8402670
[TBL] [Abstract][Full Text] [Related]
13. Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis.
Burgio DE; Gosland MP; McNamara PJ
Biochem Pharmacol; 1996 Apr; 51(7):987-92. PubMed ID: 8651950
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interactions of cyclosporine with etoposide and mitoxantrone in children with acute myeloid leukemia.
Lacayo NJ; Lum BL; Becton DL; Weinstein H; Ravindranath Y; Chang MN; Bomgaars L; Lauer SJ; Sikic BI; Dahl GV
Leukemia; 2002 May; 16(5):920-7. PubMed ID: 11986955
[TBL] [Abstract][Full Text] [Related]
15. Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide.
Cárcel-Trullols J; Torres-Molina F; Araico A; Saadeddin A; Peris JE
Cancer Chemother Pharmacol; 2004 Aug; 54(2):153-60. PubMed ID: 15114410
[TBL] [Abstract][Full Text] [Related]
16. Predicting etoposide toxicity: relationship to organ function and protein binding.
Joel SP; Shah R; Clark PI; Slevin ML
J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
[TBL] [Abstract][Full Text] [Related]
17. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer.
Rushing DA; Raber SR; Rodvold KA; Piscitelli SC; Plank GS; Tewksbury DA
Cancer; 1994 Aug; 74(3):834-41. PubMed ID: 8039111
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients.
Chambers SK; Chambers JT; Davis CA; Kohorn EI; Schwartz PE; Lorber MI; Handschumacher RE; Pizzorno G
J Clin Oncol; 1997 May; 15(5):1945-52. PubMed ID: 9164206
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors.
Budman DR; Igwemezie LN; Kaul S; Behr J; Lichtman S; Schulman P; Vinciguerra V; Allen SL; Kolitz J; Hock K
J Clin Oncol; 1994 Sep; 12(9):1902-9. PubMed ID: 8083713
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
Dahl GV; Lacayo NJ; Brophy N; Dunussi-Joannopoulos K; Weinstein HJ; Chang M; Sikic BI; Arceci RJ
J Clin Oncol; 2000 May; 18(9):1867-75. PubMed ID: 10784627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]